Olanzapine vs haloperidol: treating delirium in a critical care setting
Identifieur interne : 002D17 ( Main/Exploration ); précédent : 002D16; suivant : 002D18Olanzapine vs haloperidol: treating delirium in a critical care setting
Auteurs : Yoanna K. Skrobik [Canada] ; Nicolas Bergeron [Canada] ; Marc Dumont [Canada] ; Stewart B. Gottfried [Canada]Source :
- Intensive care medicine : (Print) [ 0342-4642 ] ; 2004.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Objective: To compare the safety and estimate the response profile of olanzapine, a second-generation antipsychotic, to haloperidol in the treatment of delirium in the critical care setting. Design: Prospective randomized trial Setting: Tertiary care university affiliated critical care unit. Patients: All admissions to a medical and surgical intensive care unit with a diagnosis of delirium. Interventions: Patients were randomized to receive either enteral olanzapine or haloperidol. Measurements: Patient's delirium severity and benzodiazepine use were monitored over 5 days after the diagnosis of delirium. Main results: Delirium Index decreased over time in both groups, as did the administered dose of benzodiazepines. Clinical improvement was similar in both treatment arms. No side effects were noted in the olanzapine group, whereas the use of haloperidol was associated with extrapyramidal side effects. Conclusions: Olanzapine is a safe alternative to haloperidol in delirious critical care patients, and may be of particular interest in patients in whom haloperidol is contraindicated.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000985
- to stream PascalFrancis, to step Curation: 000338
- to stream PascalFrancis, to step Checkpoint: 000862
- to stream Main, to step Merge: 003084
- to stream Main, to step Curation: 002D17
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Olanzapine vs haloperidol: treating delirium in a critical care setting</title><author><name sortKey="Skrobik, Yoanna K" sort="Skrobik, Yoanna K" uniqKey="Skrobik Y" first="Yoanna K." last="Skrobik">Yoanna K. Skrobik</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Critical Care, Maisonneuve Rosemont Hospital, Université de Montreal, 5415 boul de l'Assomption</s1><s2>Montreal, Quebec, HIT 2M4</s2><s3>CAN</s3><sZ>1 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Montreal, Quebec, HIT 2M4</wicri:noRegion></affiliation></author><author><name sortKey="Bergeron, Nicolas" sort="Bergeron, Nicolas" uniqKey="Bergeron N" first="Nicolas" last="Bergeron">Nicolas Bergeron</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of psychiatry, CHUM (pavilion Notre Dame Université de Montréal)</s1><s2>Montreal, Quebec</s2><s3>CAN</s3><sZ>2 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Montreal, Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Dumont, Marc" sort="Dumont, Marc" uniqKey="Dumont M" first="Marc" last="Dumont">Marc Dumont</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Corev Group</s1><s2>Montreal, Quebec</s2><s3>CAN</s3><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Corev Group</wicri:noRegion></affiliation></author><author><name sortKey="Gottfried, Stewart B" sort="Gottfried, Stewart B" uniqKey="Gottfried S" first="Stewart B." last="Gottfried">Stewart B. Gottfried</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Division of Respiratory and Critical Care, Department of Medicine, McGill University Health Centre</s1><s2>Montreal, Quebec</s2><s3>CAN</s3><sZ>4 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Montreal, Quebec</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">04-0366721</idno><date when="2004">2004</date><idno type="stanalyst">PASCAL 04-0366721 INIST</idno><idno type="RBID">Pascal:04-0366721</idno><idno type="wicri:Area/PascalFrancis/Corpus">000985</idno><idno type="wicri:Area/PascalFrancis/Curation">000338</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000862</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000862</idno><idno type="wicri:doubleKey">0342-4642:2004:Skrobik Y:olanzapine:vs:haloperidol</idno><idno type="wicri:Area/Main/Merge">003084</idno><idno type="wicri:Area/Main/Curation">002D17</idno><idno type="wicri:Area/Main/Exploration">002D17</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Olanzapine vs haloperidol: treating delirium in a critical care setting</title><author><name sortKey="Skrobik, Yoanna K" sort="Skrobik, Yoanna K" uniqKey="Skrobik Y" first="Yoanna K." last="Skrobik">Yoanna K. Skrobik</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Critical Care, Maisonneuve Rosemont Hospital, Université de Montreal, 5415 boul de l'Assomption</s1><s2>Montreal, Quebec, HIT 2M4</s2><s3>CAN</s3><sZ>1 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Montreal, Quebec, HIT 2M4</wicri:noRegion></affiliation></author><author><name sortKey="Bergeron, Nicolas" sort="Bergeron, Nicolas" uniqKey="Bergeron N" first="Nicolas" last="Bergeron">Nicolas Bergeron</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of psychiatry, CHUM (pavilion Notre Dame Université de Montréal)</s1><s2>Montreal, Quebec</s2><s3>CAN</s3><sZ>2 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Montreal, Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Dumont, Marc" sort="Dumont, Marc" uniqKey="Dumont M" first="Marc" last="Dumont">Marc Dumont</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Corev Group</s1><s2>Montreal, Quebec</s2><s3>CAN</s3><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Corev Group</wicri:noRegion></affiliation></author><author><name sortKey="Gottfried, Stewart B" sort="Gottfried, Stewart B" uniqKey="Gottfried S" first="Stewart B." last="Gottfried">Stewart B. Gottfried</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Division of Respiratory and Critical Care, Department of Medicine, McGill University Health Centre</s1><s2>Montreal, Quebec</s2><s3>CAN</s3><sZ>4 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Montreal, Quebec</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Intensive care medicine : (Print)</title><title level="j" type="abbreviated">Intensive care med. : (Print)</title><idno type="ISSN">0342-4642</idno><imprint><date when="2004">2004</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Intensive care medicine : (Print)</title><title level="j" type="abbreviated">Intensive care med. : (Print)</title><idno type="ISSN">0342-4642</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Delirium</term><term>Haloperidol</term><term>Intensive care</term><term>Olanzapine</term><term>Parkinson disease</term><term>Resuscitation</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term><term>Olanzapine</term><term>Halopéridol</term><term>Traitement</term><term>Délirium</term><term>Réanimation</term><term>Soin intensif</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective: To compare the safety and estimate the response profile of olanzapine, a second-generation antipsychotic, to haloperidol in the treatment of delirium in the critical care setting. Design: Prospective randomized trial Setting: Tertiary care university affiliated critical care unit. Patients: All admissions to a medical and surgical intensive care unit with a diagnosis of delirium. Interventions: Patients were randomized to receive either enteral olanzapine or haloperidol. Measurements: Patient's delirium severity and benzodiazepine use were monitored over 5 days after the diagnosis of delirium. Main results: Delirium Index decreased over time in both groups, as did the administered dose of benzodiazepines. Clinical improvement was similar in both treatment arms. No side effects were noted in the olanzapine group, whereas the use of haloperidol was associated with extrapyramidal side effects. Conclusions: Olanzapine is a safe alternative to haloperidol in delirious critical care patients, and may be of particular interest in patients in whom haloperidol is contraindicated.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Skrobik, Yoanna K" sort="Skrobik, Yoanna K" uniqKey="Skrobik Y" first="Yoanna K." last="Skrobik">Yoanna K. Skrobik</name></noRegion><name sortKey="Bergeron, Nicolas" sort="Bergeron, Nicolas" uniqKey="Bergeron N" first="Nicolas" last="Bergeron">Nicolas Bergeron</name><name sortKey="Dumont, Marc" sort="Dumont, Marc" uniqKey="Dumont M" first="Marc" last="Dumont">Marc Dumont</name><name sortKey="Gottfried, Stewart B" sort="Gottfried, Stewart B" uniqKey="Gottfried S" first="Stewart B." last="Gottfried">Stewart B. Gottfried</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D17 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002D17 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:04-0366721
|texte= Olanzapine vs haloperidol: treating delirium in a critical care setting
}}
| This area was generated with Dilib version V0.6.29. |  |